Tomocube, Inc. · KRX:475960
Tomocube — Investor Presentation (December 2024)
43 slides from Tomocube's investor presentation, Dec 5, 2024
Slide 1: Innovate the way we see life
Innovate the way we see life Investor Relations 2024 Tomocube, Inc.
Slide 2: Disclaimer
Disclaimer This material is prepared by Tomocube, Inc. (“the Company”) for information purposes in presentations for investors. The “forward-looking information” in this material has not been verified individually. It relates to future events rather than past ones and includes the Company’s anticipa
Slide 3: Table of contents
Table of contents Prologue Chapter 1. Why Holotomography(HT) Chapter 2. Expanding the applications of HT Chapter 3. Investment Highlights Appendix
Slide 4: Paradigm Shift in Cell Analysis
Prologue Tomocube, Inc. I 4 Paradigm Shift in Cell Analysis Growth drivers in 3D Biology & Regenerative Medicine Market NEW era 3D Biology, Regenerative Medicine Organoids Cell Therapies organoids and cell therapies can be utilized in drug development, companion Complex 3D organ-mimicking structures
Slide 5: Need for Holotomography
Prologue Tomocube, Inc. I 5 Need for Holotomography Addressing Unmet Needs in Advanced Biomedical Industry Conventional HT(“Holotomography”) Holotomography Effects Unsuitable for therapeutic Applicable for therapeutic Fluorescence-based purposes imaging application Label-free cell analysis Exclusive
Slide 6: Setting new standards in cell analysis via Holotomography
Prologue Tomocube, Inc. I 6 Setting new standards in cell analysis via Holotomography Replacing conventional CT imaging as a global standard with safer, more economical and efficient technologies CT Similarity HT (Computed tomography) (Holotomography) X-ray Light source Laser, LED Cells, Human Speci
Slide 7: Leading Advanced Bio/Medical Industry
Prologue Tomocube, Inc. I 7 Leading Advanced Bio/Medical Industry World-Class Holotomography Development & Commercialization Paradigm Shift in Bioimaging 3D Biology & Regenerative Medicine Evolution of cell imaging technologies during the bio-analysis paradigm shift 3D Cell Structure Measurement & A
Slide 8: Cancer cell
@ Cancer cell Tomocube Label-free 3D t Dovel imagine, . Cellular Responses and Recovery from High Leviélaf Redktive Oxygen Species (ROS) * Cell line: Hep3B I * Microscope: HT-X1 VES * Observation duration: 4.5 hr + Time interval: 20 sec * Chip: ibidi u-Slide | Luer + Flow rate: 0.23 yL/min 20 um
Slide 9: Organoid
Cancer cell ©: Organoid Tomocube So Unveiling the unseen: 3D Organoid visualization 6 Cell division #(116/361) 00:57:30
Slide 10: Why Holotomography (HT)
Chapter 1. Why Holotomography (HT) 01. Benefits from HT 02. HT Platform (1) Hardware (2) Software (3) AI 03. Distinct Competitive Advantages (1) Holotomography Comparison (2) Cell Analysis Technology Comparison 04. Externally Validated Technological Capability
Slide 11: 01. Benefits of HT
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 11 01. Benefits of HT Able to secure a competitive business model via proprietary hardware & software products Holotomography Platform Hardware Software AI 00:00 h 19:00 h Lipid droplet Volume: 40.265 (µ㎥) Volume: 345.305 (µ㎥) Mean conc.: 1.367 Mean
Slide 12: 02. HT Platform (1) Hardware
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 12 02. HT Platform (1) Hardware 3D Label-Free Imaging Technology Standard Protocol Unmet Needs Hardware Competencies Limitations of Observes cells in their original state Accurate 3D cell analysis for thick Labeling without compromising cell viabili
Slide 13: 02. HT Platform (2) Software
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 13 02. HT Platform (2) Software Development of Custom Solutions for Specific Applications Expanded application areas Software Competencies through AI model-based software 2022 2024 TomoAnalysis 1.0 TomoAnalysis 2.0 Demand-Based Solution Development
Slide 14: 02. HT Platform (3) AI
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 14 02. HT Platform (3) AI World-Leading AI-Based HT Imaging Analysis & Biomarker Discovery 01 02 Quality Improvement via AI Automated Cell/Organelle Segmentation Maximizing HT imaging definition Automated quantitative analysis of & regeneration spee
Slide 15: 03. Distinct Competitive Advantages: Holotomography Comparison
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 15 03. Distinct Competitive Advantages: Holotomography Comparison Tomocube’s Journey Defines Holotomography’s History HT Technology Paradigm Shifts & Milestones 1st Generation 2nd Generation Future 1st Gen HT 1st Gen HT Category 2nd Gen HT (Tomocube
Slide 16: 03. Distinct Competitive Advantages: Cell Analysis Technology Comparison
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 16 03. Distinct Competitive Advantages: Cell Analysis Technology Comparison Tomocube Outperforms Competitors in All Aspects of Cell Analysis Necessary Specs Comparison with Other Optical Devices 2nd GEN HT 3D Multimodal Artificial Category Resolutio
Slide 17: 04. Externally Validated Technology with strong IP protection
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 17 04. Externally Validated Technology with strong IP protection 71 Granted and Pending Patents; Domestic & International Recognition • Research in HT precision Foundational research in label-free • Developed • Developed AI-based Initiated research
Slide 18: Expanding the applications of HT
Chapter 2. Expanding the applications of HT 01. Tomocube’s Target Market 02. Opportunity # 1 Organoids Opportunity # 2 In Vitro Fertilization Opportunity # 3 Cell Therapies Opportunity # 4 Drug Development Opportunity # 5 Non-Bio Industrial Applications
Slide 19: 01. Tomocube's Target Market
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 19 01. Tomocube’s Target Market 3D Biology & Regenerative Medicine Market Growth Market Size Projection 2027 Approx. 120 trillion KRW+ α Organoids In Vitro Fertilization (IVF) Cell Therapy High-Content Screening Organoid analysis in live c
Slide 20: 02. Expanding Applications of HT(1): Organoids
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 20 02. Expanding Applications of HT(1): Organoids* Organoids as a new model in Advanced Bioindustry Animal Testing Termination Organoid-based Alternative R&D using organioids bio/pharmaceutical USA(2022), EU(2025) paradigm shift Top 15 glo
Slide 21: 02. Expanding Applications of HT(1): Organoids
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 21 02. Expanding Applications of HT(1): Organoids Standardization of Organoid Analysis Using HT Collaboration with Global Top Pharmas Collaborating w/ US-KOR Gov’t Agencies In conversation to co-develop industry standards Selected for bio
Slide 22: 02. Expanding Applications of HT(2): IVF
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 22 02. Expanding Applications of HT(2): IVF 3D Label-Free HT Imaging & AI for High Implantation Rate Embryo Selection Conventional Unmet Needs Synergies from strategic partnerships • Label-less imaging is essential for embryo selection pro
Slide 23: 02. Expanding Applications of HT(3): Cell Therapy
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 23 02. Expanding Applications of HT(3): Cell Therapy Revolutionary Solution for QC in Cell Therapy Production Processes HT powered analysis S/W allowing Non-invasive QC Process for Cell Therapy Improvements in cell therapeutics manufacturi
Slide 24: 02. Expanding Applications of HT(4): Drug Development
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 24 02. Expanding Applications of HT(4): Drug Development Application of HT in Phenotypic Drug Discovery (PDD) Improving Phenotypic Drug Discovery with HT and AI Entering new PDD markets using AI TDD Target-Based Drug Discovery feature extr
Slide 25: 02. Expanding Applications of HT(5): Non-Bio Industrial Use
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 25 02. Expanding Applications of HT(5): Non-Bio Industrial Use HT-Based Inspection in Semiconductor Advanced Packaging 3D analysis of Wafer (Hybrid Bonding) Post CMP Testing Improving advanced packaging by high-def imaging of wafers Measur
Slide 26: 02. Expanding Applications of HT(5): Non-Bio Industrial Use
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 26 02. Expanding Applications of HT(5): Non-Bio Industrial Use Glass Substrate testing market Non-invasive 3D Inspection of Laser modulation and internal crack testing Through Glass Via(TGV) Improving glass substrate qualities by High-reso
Slide 27: 02. Expanding Applications of HT(5): Non-Bio Industrial Use
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 27 02. Expanding Applications of HT(5): Non-Bio Industrial Use Continuous R&D enabling the expansions beyond semicon and display sectors New product launching 3D measurement modules & device Early Providing modules to machinery/device make
Slide 28: 02. Expanding Applications of HT(5): Non-Bio Industrial Use
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 28 02. Expanding Applications of HT(5): Non-Bio Industrial Use Peer Group Comparison in Non-Bio Inspection Market Internal testing w/o Company Name Market cap1 Sales(FY2023) Specialties High-def 3D Imaging High-speed testing damaging Hybri
Slide 29: Investment Highlights
Chapter 3. Investment Highlights 01. Tomocube’s Key Success Factors 02. Proven Technology 03. Commercial Viability 04. Global Market Expansion 05. Downstream industry application & investments 06. Domestic/Global leader in bio materials/parts/equipment 07. Earnings guidance
Slide 30: 01. Tomocube's Success Factors
Chapter 3. Investment Highlights Tomocube, Inc. I 30 01. Tomocube’s Success Factors Advanced Deep Tech Innovator in Bio Industry First Player Sufficient Capitals World’s First Commercialization of 2nd Gen Investment from Major Global Holotomography Companies and VCs Mkt. Cap. Tomocube 5 + yrs HT Com
Slide 31: 02. Proven Technological Excellence
Chapter 3. Investment Highlights Tomocube, Inc. I 31 02. Proven Technological Excellence Holotomography Recognition in Global Market Tomocube is leading global technology developments Major International Collaborations and Holotomography featured in top publications by industry Conferences Competiti
Slide 32: 03. Proven Commercial Viability
Chapter 3. Investment Highlights Tomocube, Inc. I 32 03. Proven Commercial Viability HT Expected to Show Explosive Growth as Best-in-Class Technology High satisfaction from customer base Continuous Revenue Pipeline Growth HT Demo provisions(cumulated) Unit : EA HT purchase 226 New Customer 175 - Hig
Slide 33: 04. Global Expansion Strategy
Chapter 3. Investment Highlights Tomocube, Inc. I 33 04. Global Expansion Strategy Expansion of Direct Sales & Distribution Networks Globally Global expansion Quality references Extensive B/D and marketing Tomocube Europe Tomocube USA 5 distributor customers across D2C & North America 14 Distributor
Slide 34: 05. Strategic Investment to Meet Market Demand Expansion
Chapter 3. Investment Highlights Tomocube, Inc. I 34 05. Strategic Investment to Meet Market Demand Expansion Increased Demand in Bio & Non-Bio Sectors, Market Positioning Capacity Expansion for bio CapEx for non-bio products products Capacity 4.5x 300 units High-Level Clean Room For Semiconductor/D
Slide 35: 06. Leading Localization in Bio Equipment Manufacturing
Chapter 3. Investment Highlights Tomocube, Inc. I 35 06. Leading Localization in Bio Equipment Manufacturing Direct Beneficiary of Government’s Bio Equipment Localization Policy KR Government’s subsidy on 5% or less for cell analysis domestic device R&D equipment and other device dev. “20% or more t
Slide 36: 07. Financial Guidance
Chapter 3. Investment Highlights Tomocube, Inc. I 36 07. Financial Guidance Holotomography Sales Growth Projected to Drive Profitability from 2026 Market & Business Validation Achieved Growth in Revenue & Profit Sales Revenue / OP Guidelines (Units: KRW mn.) Sales Operating Profit / Loss 29,060 Long
Slide 37: Appendix
Appendix 01. Financial Summary 02. Company Overview 03. Management (1) CEO (2) Key Personnel 04. Board of Directors
Slide 38: 01. Summary Financial Statements
Appendix Tomocube, Inc. I 38 01. Summary Financial Statements Statement of Financial Position Unit : million KRW Income Statement Unit : million KRW Category 2021 2022 2023 2024.1H Category 2021 2022 2023 2024.1H Current Assets 27,700 22,126 15,952 11,895 Sales 1,625 1,871 3,747 2,928 Non-Current As
Slide 39: 02. Company Overview
Appendix Tomocube, Inc. I 39 02. Company Overview Company Overview Establishments Company Tomocube, Inc. Name KAIST Co-CEOs Paul Park, Hyung-Keun Hong (Co-CEOs) Established from a KAIST World-leading developer of holotomography Laboratory in 2015 Technology and products Founded August 24, 2015 Best
Slide 40: 03. Man Power (1) CEO
Appendix Tomocube, Inc. I 40 03. Man Power (1) CEO Collaboration Between Leading Experts in Bio Research and Startup Professionals Holography, Bio imaging, AI specific industry leader Education Ph.D., Harvard-MIT Health Science and Technology Career Professor in Department of Physics at KAIST Direct
Slide 41: 03. Man Power (2) Senior Executives
Appendix Tomocube, Inc. I 41 03. Man Power (2) Senior Executives More than 10 years of experienced management and development personnel in the relevant field Jae-Pil Do Technology Development Department Sung-Ho Ko COO Education Ph.D. in BioMEMS, University of Cincinnati Education M.S. in Industrial
Slide 42: 04. Board of Directors
Appendix Tomocube, Inc. I 42 04. Board of Directors Independent, professional board with a focus on accountability Young-Keun Park Chairman of the Board, CEO Sang-Il Park Outside Director Education Ph.D. in Health Science and Technology, Harvard-MIT Education Ph.D., Stanford University Career Co-fou
Slide 43: Tomocube
4} Tomocube